Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of non-ST-segment elevation acute coronary syndromes

Matthias Schwenkglenks; John E Brazier; Thomas D Szucs; Keith A A Fox

doi:10.1016/j.jval.2010.10.025

Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of non-ST-segment elevation acute coronary syndromes

Matthias Schwenkglenks, John E Brazier, Thomas D Szucs, Keith A A Fox

Research output: Contribution to journal › Article › peer-review

Abstract

This study sought to assess the cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor (GPI) in thienopyridine-treated non-ST-segment elevation acute coronary syndrome (NSTE-ACS) patients undergoing early or urgent invasive management, from a United Kingdom National Health Service perspective.

Original language	English
Pages (from-to)	24-33
Number of pages	10
Journal	Value in Health
Volume	14
Issue number	1
DOIs	https://doi.org/10.1016/j.jval.2010.10.025
Publication status	Published - 2011

Access to Document

10.1016/j.jval.2010.10.025

Cite this

@article{c34ae0b9fb484fcda6f8faa2517a4b51,

title = "Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of non-ST-segment elevation acute coronary syndromes",

abstract = "This study sought to assess the cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor (GPI) in thienopyridine-treated non-ST-segment elevation acute coronary syndrome (NSTE-ACS) patients undergoing early or urgent invasive management, from a United Kingdom National Health Service perspective.",

author = "Matthias Schwenkglenks and Brazier, {John E} and Szucs, {Thomas D} and Fox, {Keith A A}",

year = "2011",

doi = "10.1016/j.jval.2010.10.025",

language = "English",

volume = "14",

pages = "24--33",

journal = "Value in Health",

issn = "1098-3015",

publisher = "ELSEVIER SCIENCE INC",

number = "1",

}

TY - JOUR

T1 - Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of non-ST-segment elevation acute coronary syndromes

AU - Schwenkglenks, Matthias

AU - Brazier, John E

AU - Szucs, Thomas D

AU - Fox, Keith A A

PY - 2011

Y1 - 2011

N2 - This study sought to assess the cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor (GPI) in thienopyridine-treated non-ST-segment elevation acute coronary syndrome (NSTE-ACS) patients undergoing early or urgent invasive management, from a United Kingdom National Health Service perspective.

AB - This study sought to assess the cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor (GPI) in thienopyridine-treated non-ST-segment elevation acute coronary syndrome (NSTE-ACS) patients undergoing early or urgent invasive management, from a United Kingdom National Health Service perspective.

UR - http://www.scopus.com/inward/record.url?scp=79952664527&partnerID=8YFLogxK

U2 - 10.1016/j.jval.2010.10.025

DO - 10.1016/j.jval.2010.10.025

M3 - Article

C2 - 21211483

VL - 14

SP - 24

EP - 33

JO - Value in Health

JF - Value in Health

SN - 1098-3015

IS - 1

ER -

Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of non-ST-segment elevation acute coronary syndromes

Abstract

Access to Document

Other files and links

Fingerprint

Cite this